8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
May 8, 2026·SEC
Material company update
Apr 15, 2026·SEC
Tango Therapeutics, Inc.(TNGX)Earnings, Financials & Key Ratios
TNGX•NASDAQ
Price updated Jun 19, 2026
AboutTango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.Show more
- Revenue$62M+48.3%
- EBITDA-$109M+23.8%
- Net Income-$102M+22.0%
- EPS (Diluted)-0.87+26.9%
- Gross Margin96.34%-3.7%
- EBITDA Margin-174.74%+48.6%
- Operating Margin-178.39%+48.5%
- Net Margin-162.85%+47.4%
- ROE-37.23%+35.3%
TNGX Key Insights
Tango Therapeutics, Inc. (TNGX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 97 (top 3%)
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 52.1%
✗Weaknesses
- ✗Profits declining 14.3% over 5 years
- ✗Negative free cash flow
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when TNGX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TNGX Price & Volume
Tango Therapeutics, Inc. (TNGX) stock price & volume — 10-year historical chart
Loading chart...
TNGX Growth Metrics
Tango Therapeutics, Inc. (TNGX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years52.13%
3 Years35.89%
TTM39.04%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM18.93%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM31.41%
Return on Capital
10 Years-37.1%
5 Years-31.16%
3 Years-36.93%
Last Year-33.96%
TNGX Recent Earnings
Tango Therapeutics, Inc. (TNGX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 5/12 qtrs (50%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.32-2.0%
$0.31
Rev
—
$578,091
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.29+6.5%
$0.31
Rev
—
$500,400
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.13+1200.0%
$0.01
Rev
$54M+9578.2%
$556,000
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.35+0.0%
$0.35
Rev
$3M-50.3%
$6M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.32vs $0.31-2.0% | —vs $578,091 |
| Q2 2026 | Mar 5, 2026 | $0.29vs $0.31+6.5% | —vs $500,400 |
| Q4 2025 | Nov 4, 2025 | $0.13vs $0.01+1200.0% | $54Mvs $556,000+9578.2% |
| Q3 2025 | Aug 5, 2025 | $0.35vs $0.35+0.0% | $3Mvs $6M-50.3% |
Based on last 12 quarters of dataView full earnings history →
TNGX Peer Comparison
Tango Therapeutics, Inc. (TNGX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RVMD | 34.65B | 162.99 | -27.39 | -83.22% | 0.10 | |||
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 AUPH | 2.12B | 16.46 | 7.95 | 20.38% | 99.97% | 64.48% | 0.13 | |
 PMVP | 60.26M | 1.13 | -0.76 | -68.98% | 0.01 | |||
 ARQT | 3.28B | 26.21 | -201.62 | 91.34% | -0.57% | -1.41% | 0.03 | |
 NUVL | 9.08B | 123.43 | -21.10 | -42.78% | ||||
 TYRA | 1.68B | 28.32 | -14.09 | -42.66% | 0.02 |
Compare TNGX vs Peers
Tango Therapeutics, Inc. (TNGX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TNGX Income Statement
Tango Therapeutics, Inc. (TNGX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 24.65M | 7.66M | 37.04M | 24.86M | 36.53M | 42.07M | 62.38M | 56.99M |
Revenue Growth % | - | -68.94% | 383.83% | -32.89% | 46.93% | 15.17% | 48.29% | 39.04% |
Cost of Goods Sold | 32.27M | 1.63M | 0 | 0 | 0 | 0 | 2.28M | 1.57M |
COGS % of Revenue | 130.93% | 21.23% | - | - | - | - | 3.66% | - |
Gross Profit | -7.63M▲ 0% | 6.03M▲ 179.1% | 37.04M▲ 514.2% | 24.86M▼ 32.9% | 36.53M▲ 46.9% | 42.07M▲ 15.2% | 60.1M▲ 42.9% | 55.42M▲ 0% |
Gross Margin % | -30.93% | 78.77% | 100% | 100% | 100% | 100% | 96.34% | 97.25% |
Gross Profit Growth % | - | 179.1% | 514.19% | -32.89% | 46.93% | 15.17% | 42.87% | - |
Operating Expenses | 7.54M | 58.23M | 95.23M | 135.93M | 150.7M | 187.66M | 171.39M | 172.95M |
OpEx % of Revenue | 30.58% | 760.59% | 257.09% | 546.79% | 412.57% | 446.09% | 274.74% | - |
Selling, General & Admin | 7.54M | 8.24M | 17.6M | 30.02M | 35.5M | 43.75M | 41.51M | 45.26M |
SG&A % of Revenue | 30.58% | 107.63% | 47.5% | 120.78% | 97.19% | 103.99% | 66.54% | - |
Research & Development | 32.27M | 49.99M | 77.64M | 105.91M | 115.2M | 143.92M | 132.16M | 129.35M |
R&D % of Revenue | 130.93% | 652.97% | 209.59% | 426.01% | 315.38% | 342.1% | 211.86% | - |
Other Operating Expenses | -32.27M | 0 | 0 | 0 | 0 | 0 | -2.28M | -1000K |
Operating Income | -15.16M▲ 0% | -52.2M▼ 244.3% | -58.19M▼ 11.5% | -111.07M▼ 90.9% | -114.17M▼ 2.8% | -145.59M▼ 27.5% | -111.29M▲ 23.6% | -117.53M▲ 0% |
Operating Margin % | -61.51% | -681.82% | -157.09% | -446.79% | -312.57% | -346.09% | -178.39% | -206.22% |
Operating Income Growth % | - | -244.28% | -11.48% | -90.88% | -2.79% | -27.52% | 23.56% | - |
EBITDA | -14.52M | -50.58M | -57.29M | -109.46M | -111.76M | -143.1M | -109.01M | -115.41M |
EBITDA Margin % | -58.9% | -660.59% | -154.67% | -440.32% | -305.96% | -340.15% | -174.74% | -202.5% |
EBITDA Growth % | - | -248.34% | -13.28% | -91.06% | -2.1% | -28.04% | 23.82% | 19.51% |
D&A (Non-Cash Add-back) | 643K | 1.63M | 897K | 1.61M | 2.42M | 2.5M | 2.28M | 2.12M |
EBIT | -15.16M | -51.97M | -58.19M | -111.07M | -114.17M | -145.59M | -111.29M | -115.38M |
Net Interest Income | 684K | 108K | 495K | 1.46M | 6.62M | 7.89M | 5.63M | 6.19M |
Interest Income | 684K | 108K | 495K | 1.46M | 6.62M | 7.89M | 5.63M | 6.19M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 1.07M | 228K | 247K | 2.95M | 12.56M | 15.5M | 9.7M | 10.27M |
Pretax Income | -14.1M▲ 0% | -51.97M▼ 268.7% | -57.94M▼ 11.5% | -108.12M▼ 86.6% | -101.61M▲ 6.0% | -130.09M▼ 28.0% | -101.59M▲ 21.9% | -107.26M▲ 0% |
Pretax Margin % | -57.18% | -678.84% | -156.43% | -434.92% | -278.18% | -309.24% | -162.85% | -188.2% |
Income Tax | 0 | 0 | 292K | 54K | 134K | 208K | 4K | -29K |
Effective Tax Rate % | 0% | 0% | -0.5% | -0.05% | -0.13% | -0.16% | -0% | 0.03% |
Net Income | -14.1M▲ 0% | -51.97M▼ 268.7% | -58.23M▼ 12.1% | -108.18M▼ 85.8% | -101.74M▲ 5.9% | -130.3M▼ 28.1% | -101.59M▲ 22.0% | -107.23M▲ 0% |
Net Margin % | -57.18% | -678.84% | -157.21% | -435.14% | -278.54% | -309.73% | -162.85% | -188.15% |
Net Income Growth % | - | -268.73% | -12.05% | -85.76% | 5.95% | -28.07% | 22.03% | 18.93% |
Net Income (Continuing) | -14.1M | -51.97M | -58.23M | -108.18M | -101.74M | -130.3M | -101.59M | -107.23M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.57▲ 0% | -1.62▼ 3.2% | -0.94▲ 42.0% | -1.23▼ 30.9% | -1.08▲ 12.2% | -1.19▼ 10.2% | -0.87▲ 26.9% | -0.75▲ 0% |
EPS Growth % | - | -3.18% | 41.98% | -30.85% | 12.2% | -10.19% | 26.89% | 31.41% |
EPS (Basic) | -1.57 | -1.62 | -0.94 | -1.23 | -1.08 | -1.19 | -0.87 | - |
Diluted Shares Outstanding | 87.47M | 87.47M | 62.11M | 87.82M | 94.57M | 109.23M | 116.17M | 143.58M |
Basic Shares Outstanding | 87.47M | 87.47M | 62.11M | 87.82M | 94.57M | 109.23M | 116.17M | 143.58M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
TNGX Balance Sheet
Tango Therapeutics, Inc. (TNGX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 41.66M | 193.63M | 492.34M | 375.27M | 346.54M | 266.34M | 353.76M | 392.33M |
Cash & Short-Term Investments | 40.42M | 190.32M | 485.25M | 366.13M | 336.88M | 257.92M | 343.14M | 379.84M |
Cash Only | 22.89M | 28.38M | 142.75M | 59.97M | 66.39M | 69.53M | 112.28M | 157.83M |
Short-Term Investments | 17.54M | 161.94M | 342.51M | 306.17M | 270.5M | 188.39M | 230.86M | 222.01M |
Accounts Receivable | 0 | 2M | 2M | 2M | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | 95.35 | 19.71 | 29.36 | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 567K | 7.14M | 9.65M | 8.43M | 10.62M | 12.49M |
Total Non-Current Assets | 14.11M | 13.62M | 7.82M | 61.2M | 56.03M | 50.15M | 44.93M | 43.47M |
Property, Plant & Equipment | 11.83M | 11.3M | 6.09M | 57.77M | 53.42M | 47.58M | 42.49M | 41.03M |
Fixed Asset Turnover | 2.08x | 0.68x | 6.09x | 0.43x | 0.68x | 0.88x | 1.47x | 1.32x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 2.28M | 2.32M | 1.73M | 3.43M | 2.61M | 2.57M | 2.44M | 2.43M |
Total Assets | 55.76M▲ 0% | 207.25M▲ 271.7% | 500.15M▲ 141.3% | 436.47M▼ 12.7% | 402.57M▼ 7.8% | 316.49M▼ 21.4% | 398.69M▲ 26.0% | 435.79M▲ 0% |
Asset Turnover | 0.44x | 0.04x | 0.07x | 0.06x | 0.09x | 0.13x | 0.16x | 0.18x |
Asset Growth % | - | 271.66% | 141.33% | -12.73% | -7.77% | -21.38% | 25.97% | 6.83% |
Total Current Liabilities | 25.85M | 40.92M | 40.69M | 55.55M | 45.94M | 38.17M | 21.68M | 14.33M |
Accounts Payable | 670K | 1.84M | 3.23M | 4.45M | 2.79M | 1.6M | 1.18M | 2.43M |
Days Payables Outstanding | 7.58 | 413.52 | - | - | - | - | 189.14 | 491.95 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 2.74M | 2.83M |
Deferred Revenue (Current) | 0 | 31.98M | 26.02M | 31.79M | 25.67M | 17.62M | 0 | 23.37M |
Other Current Liabilities | 19.93M | 793K | 666K | 1.27M | 7.49M | 1.74M | 17.76M | 9.07M |
Current Ratio | 1.61x | 4.73x | 12.10x | 6.76x | 7.54x | 6.98x | 16.32x | 27.38x |
Quick Ratio | 1.61x | 4.73x | 12.10x | 6.76x | 7.54x | 6.98x | 16.32x | 27.38x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 22.01M | 127.73M | 114.72M | 131.45M | 103.52M | 78.81M | 30.83M | 29.96M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 30.83M | 29.96M |
Capital Lease Obligations | 7.88M | 6.92M | 0 | 39.36M | 36.84M | 34.04M | 0 | 94.97M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 14.12M | 5K | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 47.86M | 168.65M | 155.41M | 186.99M | 149.46M | 116.97M | 52.51M | 44.29M |
Total Debt | 8.54M | 7.88M | 1.5M | 41.13M | 38.92M | 36.49M | 33.57M | 32.79M |
Net Debt | -14.35M | -20.5M | -141.24M | -18.84M | -27.46M | -33.04M | -78.71M | -125.04M |
Debt / Equity | 1.08x | 0.20x | 0.00x | 0.16x | 0.15x | 0.18x | 0.10x | 0.08x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.28x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 1.08x |
Interest Coverage | - | - | - | - | - | - | - | - |
Total Equity | 7.91M▲ 0% | 38.6M▲ 388.3% | 344.75M▲ 793.1% | 249.48M▼ 27.6% | 253.11M▲ 1.5% | 199.52M▼ 21.2% | 346.18M▲ 73.5% | 391.51M▲ 0% |
Equity Growth % | - | 388.3% | 793.13% | -27.63% | 1.46% | -21.17% | 73.51% | 132.61% |
Book Value per Share | 0.09 | 0.44 | 5.55 | 2.84 | 2.68 | 1.83 | 2.98 | 2.73 |
Total Shareholders' Equity | 7.91M | 38.6M | 344.75M | 249.48M | 253.11M | 199.52M | 346.18M | 391.51M |
Common Stock | 13K | 40K | 88K | 88K | 102K | 108K | 136K | 144K |
Retained Earnings | -51.13M | -103.1M | -161.34M | -269.51M | -371.26M | -501.56M | -603.15M | -648.67M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 10K | 17K | -765K | -3.71M | 186K | 336K | 224K | -115K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TNGX Cash Flow Statement
Tango Therapeutics, Inc. (TNGX) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -24.8M | 70.07M | -59.53M | -109.08M | -117.98M | -131.5M | -138.89M | -141.55M |
Operating CF Margin % | -100.62% | 915.28% | -160.7% | -438.78% | -323% | -312.58% | -222.63% | - |
Operating CF Growth % | - | 382.52% | -184.95% | -83.24% | -8.16% | -11.46% | -5.62% | -34.87% |
Net Income | -14.1M | -51.97M | -58.23M | -108.18M | -101.74M | -130.3M | -101.59M | -107.23M |
Depreciation & Amortization | 643K | 718K | 897K | 1.61M | 2.42M | 2.5M | 2.28M | 2.12M |
Stock-Based Compensation | 1.69M | 1.76M | 7.83M | 14.23M | 19.08M | 28.9M | 26.43M | 29.97M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -14.74M | 890K | 1.32M | 1.75M | 234K | -849K | 1.2M | 815K |
Working Capital Changes | 1.7M | 118.67M | -11.35M | -18.49M | -37.97M | -31.75M | -67.2M | -67.23M |
Change in Receivables | 0 | -2M | 0 | 0 | 2M | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 1.17M | 1.23M | 1.1M | -1.71M | -1.18M | -825K | -670K |
Cash from Investing | 848K | -145.47M | -183.43M | 26.4M | 41.43M | 86.13M | -40.87M | -61.83M |
Capital Expenditures | -1.82M | -1.11M | -1.84M | -7.69M | -1.53M | -754K | -1.05M | -999K |
CapEx % of Revenue | 7.37% | 14.45% | 4.96% | 30.94% | 4.18% | 1.79% | 1.68% | 1.75% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 2.67M | -40K | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 11M | 80.88M | 357.32M | 1.61M | 82.41M | 47.66M | 222.5M | 302.34M |
Debt Issued (Net) | 0 | 0 | 342.11M | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 80.84M | 29.99M | 0 | 80.02M | 41.72M | 222.54M | 302.92M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 11M | 40K | -14.78M | 1.61M | 2.39M | 5.94M | -36K | -573K |
Net Change in Cash | 25.17M▲ 0% | 5.49M▼ 78.2% | 114.36M▲ 1982.4% | -81.07M▼ 170.9% | 5.85M▲ 107.2% | 2.29M▼ 60.9% | 42.75M▲ 1767.6% | 98.97M▲ 0% |
Free Cash Flow | -26.62M▲ 0% | 68.97M▲ 359.1% | -61.36M▼ 189.0% | -116.77M▼ 90.3% | -119.51M▼ 2.3% | -132.25M▼ 10.7% | -139.93M▼ 5.8% | -142.54M▲ 0% |
FCF Margin % | -108% | 900.84% | -165.66% | -469.72% | -327.18% | -314.38% | -224.31% | -250.11% |
FCF Growth % | - | 359.08% | -188.97% | -90.29% | -2.34% | -10.67% | -5.81% | -4.85% |
FCF per Share | -0.30 | 0.79 | -0.99 | -1.33 | -1.26 | -1.21 | -1.20 | -0.99 |
FCF Conversion (FCF/Net Income) | 1.76x | -1.35x | 1.02x | 1.01x | 1.16x | 1.01x | 1.37x | 1.33x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TNGX Key Ratios
Tango Therapeutics, Inc. (TNGX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -223.51% | -30.38% | -36.41% | -40.49% | -57.58% | -37.23% | -41.54% |
Return on Invested Capital (ROIC) | -671.64% | -39.39% | -38.38% | -37.53% | -55.69% | -38.47% | -44.01% |
Gross Margin | 78.77% | 100% | 100% | 100% | 100% | 96.34% | 97.25% |
Net Margin | -678.84% | -157.21% | -435.14% | -278.54% | -309.73% | -162.85% | -188.15% |
Debt / Equity | 0.20x | 0.00x | 0.16x | 0.15x | 0.18x | 0.10x | 0.08x |
FCF Conversion | -1.35x | 1.02x | 1.01x | 1.16x | 1.01x | 1.37x | 1.33x |
Revenue Growth | -68.94% | 383.83% | -32.89% | 46.93% | 15.17% | 48.29% | 39.04% |
Related:TNGX Dividend History·TNGX Revenue History·TNGX Price History·TNGX P/E History·TNGX Financial Ratios·TNGX Institutional Holders
TNGX SEC Filings & Documents
Tango Therapeutics, Inc. (TNGX) SEC filings — annual & quarterly reports (10-K, 10-Q)
TNGX Frequently Asked Questions
Tango Therapeutics, Inc. (TNGX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Tango Therapeutics, Inc. (TNGX) reported $57.0M in revenue for fiscal year 2025. This represents a 131% increase from $24.6M in 2019.
Tango Therapeutics, Inc. (TNGX) grew revenue by 48.3% over the past year. This is strong growth.
Tango Therapeutics, Inc. (TNGX) reported a net loss of $107.2M for fiscal year 2025.
Dividend & Returns
Tango Therapeutics, Inc. (TNGX) has a return on equity (ROE) of -37.2%. Negative ROE indicates the company is unprofitable.
Tango Therapeutics, Inc. (TNGX) had negative free cash flow of $142.5M in fiscal year 2025, likely due to heavy capital investments.